Background:Worldwide, more than 100 million women between the ages of 15 and 49 years
take oral contraceptive pills (OCPs). OCP use increases the risk of venous
thromboembolism (VTE) through its primary drug, ethinylestradiol, which
slows liver metabolism, promotes tissue retention, and ultimately favors
fibrinolysis inhibition and thrombosis.Purpose:To evaluate the effects of OCP use on VTE after arthroscopic shoulder
surgery.Study Design:Cohort study; Level of evidence, 3.Methods:A large national payer database (PearlDiver) was queried for patients
undergoing arthroscopic shoulder surgery. The incidence of VTE was evaluated
in female patients taking OCPs and those not taking OCPs. A matched group
was subsequently created to evaluate the incidence of VTE in similar
patients with and without OCP use.Results:A total of 57,727 patients underwent arthroscopic shoulder surgery from 2007
to 2016, and 26,365 patients (45.7%) were female. At the time of surgery,
924 female patients (3.5%) were taking OCPs. The incidence of vascular
thrombosis was 0.57% (n = 328) after arthroscopic shoulder surgery, and
there was no significant difference in the rate of vascular thrombosis in
male or female patients (0.57% vs 0.57%, respectively; P
> .99). The incidence of VTE in female patients taking and not taking
OCPs was 0.22% and 0.57%, respectively (P = .2). In a
matched-group analysis, no significant difference existed in VTE incidence
between patients with versus without OCP use (0.22% vs 0.56%, respectively;
P = .2). On multivariate analysis, hypertension (odds
ratio [OR], 2.00; P < .001) and obesity (OR, 1.43;
P = .002) were risk factors for VTE.Conclusion:OCP use at the time of arthroscopic shoulder surgery is not associated with
an increased risk of VTE. Obesity and hypertension are associated with a
greater risk for thrombolic events, although the risk remains very low. Our
findings suggest that patients taking OCPs should be managed according to
the surgeon’s standard prophylaxis protocol for arthroscopic shoulder
surgery.